Max Healthcare Institute Limited (NSE:MAXHEALTH)
India
· Delayed Price · Currency is INR 1,102.00
-27.40 (-2.43%)
Mar 28, 2025, 3:30 PM IST
Max Healthcare Institute Revenue
Max Healthcare Institute had revenue of 18.68B INR in the quarter ending December 31, 2024, with 39.95% growth. This brings the company's revenue in the last twelve months to 65.42B, up 25.86% year-over-year. In the fiscal year ending March 31, 2024, Max Healthcare Institute had annual revenue of 54.06B with 18.49% growth.
Revenue (ttm)
65.42B
Revenue Growth
+25.86%
P/S Ratio
n/a
Revenue / Employee
3.35M
Employees
19,500
Market Cap
1,066.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 54.06B | 8.43B | 18.49% |
| Mar 31, 2023 | 45.63B | 6.26B | 15.90% |
| Mar 31, 2022 | 39.37B | 14.29B | 56.96% |
| Mar 31, 2021 | 25.08B | 14.49B | 136.82% |
| Mar 31, 2020 | 10.59B | -6.35B | -37.48% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Max Healthcare Institute News
- 9 days ago - Max Healthcare unit merger aims at improved cash flow and reduced compliance burden - Business Upturn
- 19 days ago - Max Healthcare to enter long-term service agreement for New Delhi Hospital - Business Upturn
- 4 weeks ago - Top stocks to buy: Stock recommendations for the week starting March 3 - The Times of India
- 5 weeks ago - Max Healthcare shares surge 2% as UBS upgrades to ‘Buy’ rating with target price of Rs 1,200 - Business Upturn
- 5 weeks ago - UBS upgrades Max Healthcare to ‘Buy’, raises target to ₹1,200 on strong expansion visibility - Business Upturn
- 7 weeks ago - Q3 2025 Max Healthcare Institute Ltd Earnings Call Transcript - GuruFocus
- 2 months ago - Max Healthcare shares in focus: HSBC maintains Hold, sees limited downside post Q3 operational beat - Business Upturn
- 2 months ago - Max Healthcare Q3 FY25 Results: Revenue surges 40% YoY to Rs 1,868 crore, Net Profit down 17.6% YoY - Business Upturn